PL1749517T3 - Trwała farmaceutyczna kompozycja zawierająca linezolid - Google Patents

Trwała farmaceutyczna kompozycja zawierająca linezolid

Info

Publication number
PL1749517T3
PL1749517T3 PL06250227T PL06250227T PL1749517T3 PL 1749517 T3 PL1749517 T3 PL 1749517T3 PL 06250227 T PL06250227 T PL 06250227T PL 06250227 T PL06250227 T PL 06250227T PL 1749517 T3 PL1749517 T3 PL 1749517T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
linezolid
linezolid form
stable pharmaceutical
patient
Prior art date
Application number
PL06250227T
Other languages
English (en)
Inventor
Ruth Tenengauzer
Minutza Leibovici
Ben-Zion Solomon
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129715&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1749517(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL1749517T3 publication Critical patent/PL1749517T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL06250227T 2005-07-20 2006-01-17 Trwała farmaceutyczna kompozycja zawierająca linezolid PL1749517T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70143805P 2005-07-20 2005-07-20
EP06250227A EP1749517B8 (en) 2005-07-20 2006-01-17 Stable pharmaceutical composition comprising linezolid form IV

Publications (1)

Publication Number Publication Date
PL1749517T3 true PL1749517T3 (pl) 2008-12-31

Family

ID=36129715

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06250227T PL1749517T3 (pl) 2005-07-20 2006-01-17 Trwała farmaceutyczna kompozycja zawierająca linezolid

Country Status (15)

Country Link
US (1) US20070020329A1 (pl)
EP (1) EP1749517B8 (pl)
JP (1) JP2009501794A (pl)
CN (1) CN101262853A (pl)
AT (1) ATE400257T1 (pl)
AU (1) AU2006277017A1 (pl)
CA (1) CA2612481A1 (pl)
DE (1) DE602006001699D1 (pl)
DK (1) DK1749517T3 (pl)
ES (1) ES2309920T3 (pl)
HK (1) HK1097774A1 (pl)
IL (1) IL188176A0 (pl)
PL (1) PL1749517T3 (pl)
PT (1) PT1749517E (pl)
WO (1) WO2007018588A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102082A1 (en) * 2006-03-09 2007-09-13 Glenmark Pharmaceuticals Limited High oxazolidinone content solid dosage forms
WO2011080570A2 (en) * 2009-12-29 2011-07-07 Micro Labs Limited Extended release pharmaceutical composition comprising linezolid and process for preparing the same
WO2012029074A2 (en) * 2010-09-02 2012-03-08 Hetero Research Foundation Pharmaceutical compositions of linezolid
CN102885788B (zh) * 2011-07-22 2016-06-29 重庆华邦制药有限公司 一种晶型稳定的利奈唑胺片及其制备方法
WO2013088389A1 (en) * 2011-12-14 2013-06-20 Alembic Pharmaceuticals Limited Linezolid premix
CN103099792B (zh) * 2012-12-10 2014-11-26 成都欣捷高新技术开发有限公司 一种高载药量、体外快速溶出的iv晶型利奈唑胺片的制备方法
CN103893138B (zh) * 2012-12-28 2017-09-29 成都国为生物医药有限公司 一种含有利奈唑胺晶型ⅲ的片剂
CN104370846B (zh) * 2013-08-15 2017-04-12 杭州华东医药集团新药研究院有限公司 制备利奈唑胺ⅳ晶型的方法
CN104622831B (zh) * 2013-11-06 2018-06-22 江苏豪森药业集团有限公司 一种口服片剂及其制备方法
CN104173303B (zh) * 2014-08-14 2017-01-11 杭州华东医药集团新药研究院有限公司 一种含有利奈唑胺的组合物及其制备方法
CN104586812A (zh) * 2014-12-25 2015-05-06 杭州华东医药集团新药研究院有限公司 一种含有利奈唑胺的组合物及其制备方法
EP3170864B1 (en) * 2015-11-17 2018-10-17 Borealis AG High flow tpo composition with excellent balance in mechanical properties for automotive interior
CN111675669A (zh) * 2020-05-15 2020-09-18 扬子江药业集团北京海燕药业有限公司 一种利奈唑胺结晶形式及其制备方法和药物组合物
CN118059106B (zh) * 2024-04-17 2024-06-28 山东新时代药业有限公司 一种利奈唑胺抗菌制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
AR027261A1 (es) * 2000-02-02 2003-03-19 Upjohn Co Linezolid forma cristalina ii
US6444813B2 (en) * 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
US6514529B2 (en) * 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
ATE412413T1 (de) * 2000-03-22 2008-11-15 Pharmacia & Upjohn Co Llc Oxazolidin tablettenformulierung
ES2331454T1 (es) * 2003-10-16 2010-01-05 Symed Labs Limited Forma cristalina de linezolid.
JP2007504173A (ja) * 2004-06-29 2007-03-01 テバ ファーマシューティカル インダストリーズ リミティド リネゾリドのｉｖ型結晶

Also Published As

Publication number Publication date
ES2309920T3 (es) 2008-12-16
DK1749517T3 (da) 2008-11-03
CA2612481A1 (en) 2007-02-15
WO2007018588A8 (en) 2008-05-08
EP1749517B1 (en) 2008-07-09
PT1749517E (pt) 2008-09-29
WO2007018588A1 (en) 2007-02-15
EP1749517A1 (en) 2007-02-07
JP2009501794A (ja) 2009-01-22
EP1749517B8 (en) 2008-10-22
DE602006001699D1 (de) 2008-08-21
HK1097774A1 (en) 2007-07-06
CN101262853A (zh) 2008-09-10
IL188176A0 (en) 2008-03-20
ATE400257T1 (de) 2008-07-15
US20070020329A1 (en) 2007-01-25
AU2006277017A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
MX2008013304A (es) Compuestos de peptido 1 tipo glucagon.
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
MY148723A (en) Use of pinolenic acid for the treatment of obesity
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
TW200716628A (en) Novel compounds
SI1778680T1 (sl) Spirociklični cikloheksanski derivati
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
NO20075111L (no) Farmasoytisk sammensetning
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
TW200630128A (en) Active ingredient-containing silicone elastomers
TW200700071A (en) Novel use
TW200745132A (en) Novel, acyclically substituted furopyrimidine derivatives and use thereof
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
RU2007122391A (ru) S-миртазапин для лечения приливов
MX2010006608A (es) Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor.
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
PT2234966E (pt) Derivados de azetidinas, sua preparação e sua aplicação em terapia
MX2009005912A (es) Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.
MY146657A (en) Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas
TW200633717A (en) Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
ATE527997T1 (de) Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien